Pathology: breast cancer - adjuvant; es-BC - HER2 positive - (neo)adjuvant (NA); es-BC - HR positive - (neo)adjuvant (NA); la/mBC - HER2 positive - 2nd Line (L2);
| breast cancer - adjuvant | es-BC - HER2 positive - (neo)adjuvant (NA) | es-BC - HR positive - (neo)adjuvant (NA) | la/mBC - HER2 positive - 2nd Line (L2) | |||
| KATHERINE, 2019 | KATHERINE, 2019 | Harbeck (TDM-1), 2017 | Harbeck (TDM-1), 2017 | EMILIA, 2012 | ||
| trastuzumab emtansine | 5 | T1 | T1 | T1 | T1 | T1 |
| trastuzumab | 0 | T0 | T0 | |||
| trastuzumab plus endocrine therapy | 0 | T0 | T0 | |||
| lapatinib plus capecitabine | 0 | T0 | ||||